Allografting for Bosutinib, Imatinib, Nilotinib, Dasatinib, and Interferon Resistant Chronic Myeloid Leukemia Without ABL Kinase Mutation

Overview

Journal Case Rep Hematol

Publisher Wiley

Specialty Hematology

Date 2012 Sep 1

PMID 22937303

Citations 3

Authors

B Uz

O Bektas

E Eliacik

H Goker

Y Erbilgin

M Sayitoglu

N Sayinalp

S Aksu

Y Buyukasik

O Ozcebe

I C Haznedaroglu

Affiliations

Soon will be listed here.

Abstract

The current treatment of chronic phase chronic myeloid leukemia (CML) consists of oral tyrosine kinase inhibitors (TKIs). However, high-risk CML may present with an aggressive course which may result in blastic crisis or a "difficult-to-manage" state with available treatments. The aim of this paper is to report a patient with complicated CML resistant to treatment and progressed despite the administration of bosutinib, imatinib mesylate, nilotinib, dasatinib, interferon alpha 2a, cytotoxic chemotherapy, and allogeneic hematopoietic stem cell transplantation. The striking point of this case story is that no Abl kinase domain mutation against TKIs has been detected during this very complicated disease course of CML. Meanwhile, challenging cases will always be present despite the hope and progress in CML in the TKI era.

Citing Articles

WHO 2016 Definition of Chronic Myeloid Leukemia and Tyrosine Kinase Inhibitors.

Haznedaroglu I, Kuzu I, Ilhan O Turk J Haematol. 2019; 37(1):42-47.

PMID: 31612694 PMC: 7057757. DOI: 10.4274/tjh.galenos.2019.2019.0241.

Drug Therapy in the Progressed CML Patient with multi-TKI Failure.

Haznedaroglu I Mediterr J Hematol Infect Dis. 2015; 7(1):e2015014.

PMID: 25745541 PMC: 4344171. DOI: 10.4084/MJHID.2015.014.

Current management of chronic myeloid leukemia with tyrosine kinase inhibitors.

Haznedaroglu I Turk J Haematol. 2014; 30(3):247-55.

PMID: 24385803 PMC: 3878539. DOI: 10.4274/Tjh.2013.0108.

References

Remsing Rix L, Rix U, Colinge J, Hantschel O, Bennett K, Stranzl T . Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells. Leukemia. 2008; 23(3):477-85. DOI: 10.1038/leu.2008.334. View

Kaygusuz G, Kuzu I, Akpinar E, Uysal A . Extramedullary hematopoiesis in the axillary lymph node in a patient with an accelerated phase of chronic myeloid leukemia. Turk J Haematol. 2016; 26(1):40-1. View

Koca E, Haznedaroglu I . Imatinib mesylate and the management of chronic myeloid leukemia (CML). Turk J Haematol. 2016; 22(4):161-72. View

Kantarjian H, OBrien S, Talpaz M, Borthakur G, Ravandi F, Faderl S . Outcome of patients with Philadelphia chromosome-positive chronic myelogenous leukemia post-imatinib mesylate failure. Cancer. 2007; 109(8):1556-60. DOI: 10.1002/cncr.22569. View

Puttini M, Coluccia A, Boschelli F, Cleris L, Marchesi E, Donella-Deana A . In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells. Cancer Res. 2006; 66(23):11314-22. DOI: 10.1158/0008-5472.CAN-06-1199. View

Hayran M, Koca E, Haznedaroglu I, Unsal I, Durgun B, Guvenc F . Predicting chronic leukaemias from assessment of complete peripheral blood counts. J Int Med Res. 2007; 34(6):640-7. DOI: 10.1177/147323000603400609. View

Sayinalp N, Cinar H, Uner A, Haznedaroglu I, Buyukasik Y, Goker H . Plasma basic fibroblast growth factor and bone marrow fibrosis in clonal myeloproliferative disorders. Clin Lab Haematol. 2004; 26(4):265-8. DOI: 10.1111/j.1365-2257.2004.00616.x. View

OBrien S, Guilhot F, Larson R, Gathmann I, Baccarani M, Cervantes F . Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003; 348(11):994-1004. DOI: 10.1056/NEJMoa022457. View

Jones D, Thomas D, Yin C, OBrien S, Cortes J, Jabbour E . Kinase domain point mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia emerge after therapy with BCR-ABL kinase inhibitors. Cancer. 2008; 113(5):985-94. PMC: 4204653. DOI: 10.1002/cncr.23666. View

10.

Saglio G, Kim D, Issaragrisil S, le Coutre P, Etienne G, Lobo C . Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med. 2010; 362(24):2251-9. DOI: 10.1056/NEJMoa0912614. View

11.

Kantarjian H, Shah N, Hochhaus A, Cortes J, Shah S, Ayala M . Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2010; 362(24):2260-70. DOI: 10.1056/NEJMoa1002315. View

12.

Kantarjian H, Cortes J . Considerations in the management of patients with Philadelphia chromosome-positive chronic myeloid leukemia receiving tyrosine kinase inhibitor therapy. J Clin Oncol. 2011; 29(12):1512-6. PMC: 4979098. DOI: 10.1200/JCO.2010.33.9176. View

13.

Talpaz M, Shah N, Kantarjian H, Donato N, Nicoll J, Paquette R . Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med. 2006; 354(24):2531-41. DOI: 10.1056/NEJMoa055229. View

14.

Velev N, Cortes J, Champlin R, Jones D, Rondon G, Giralt S . Stem cell transplantation for patients with chronic myeloid leukemia resistant to tyrosine kinase inhibitors with BCR-ABL kinase domain mutation T315I. Cancer. 2010; 116(15):3631-7. DOI: 10.1002/cncr.25092. View

15.

Baccarani M, Cortes J, Pane F, Niederwieser D, Saglio G, Apperley J . Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol. 2009; 27(35):6041-51. PMC: 4979100. DOI: 10.1200/JCO.2009.25.0779. View

16.

Golas J, Arndt K, Etienne C, Lucas J, Nardin D, Gibbons J . SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice. Cancer Res. 2003; 63(2):375-81. View

17.

Beyazit Y, Kekilli M, Haznedaroglu I . Second-generation BCR-ABL kinase inhibitors in CML. N Engl J Med. 2010; 363(17):1673. DOI: 10.1056/NEJMc1007927. View

18.

Cobankara V, Oran B, Ozatli D, Haznedaroglu I, Kosar A, Buyukasik Y . Cytokines, endothelium, and adhesive molecules in pathologic thrombopoiesis. Clin Appl Thromb Hemost. 2001; 7(2):126-30. DOI: 10.1177/107602960100700209. View

19.

Baccarani M, Rosti G, Castagnetti F, Haznedaroglu I, Porkka K, Abruzzese E . Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study. Blood. 2009; 113(19):4497-504. DOI: 10.1182/blood-2008-12-191254. View